Sivik Global Healthcare LLC Increases Stake in Stryker Corporation $SYK

Sivik Global Healthcare LLC raised its holdings in Stryker Corporation (NYSE:SYK) by 8.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 19,000 shares of the medical technology company’s stock after acquiring an additional 1,500 shares during the quarter. Stryker comprises 2.0% of Sivik Global Healthcare LLC’s portfolio, making the stock its 10th largest position. Sivik Global Healthcare LLC’s holdings in Stryker were worth $7,517,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Consolidated Portfolio Review Corp boosted its stake in Stryker by 4.2% in the second quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock valued at $256,000 after acquiring an additional 26 shares during the last quarter. Sunflower Bank N.A. boosted its stake in Stryker by 4.0% in the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after acquiring an additional 27 shares during the last quarter. Pitti Group Wealth Management LLC boosted its position in shares of Stryker by 3.2% during the second quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock worth $341,000 after purchasing an additional 27 shares in the last quarter. Sachetta LLC boosted its position in shares of Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares in the last quarter. Finally, Comprehensive Financial Consultants Institutional Inc. boosted its position in shares of Stryker by 0.6% during the second quarter. Comprehensive Financial Consultants Institutional Inc. now owns 4,546 shares of the medical technology company’s stock worth $1,799,000 after purchasing an additional 28 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on SYK. Wells Fargo & Company lifted their price target on shares of Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Redburn Partners set a $420.00 price target on shares of Stryker in a research report on Thursday, September 18th. Evercore ISI reduced their price target on shares of Stryker from $418.00 to $410.00 and set an “outperform” rating on the stock in a research report on Tuesday. Truist Financial set a $415.00 price target on shares of Stryker and gave the stock a “hold” rating in a research report on Monday, August 4th. Finally, Rothschild & Co Redburn assumed coverage on shares of Stryker in a research report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target on the stock. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $430.10.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Stryker Trading Down 1.5%

Shares of NYSE:SYK opened at $364.77 on Friday. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The company’s fifty day simple moving average is $380.25 and its 200 day simple moving average is $378.83. The firm has a market cap of $139.46 billion, a price-to-earnings ratio of 48.31, a PEG ratio of 2.63 and a beta of 0.94.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. During the same period last year, the business posted $2.81 earnings per share. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, research analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s payout ratio is presently 44.50%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.